Panbela Announces Regain of Worldwide Rights to Develop and Commercialise FlynpoviTM
Tuesday, April 11, 2023
Panbela Therapeutics announced that it has regained the North American rights to develop and commercialise Flynpovi (the combination of CPP-1X (eflornithine) and sulindac) in patients with familial adenomatous polyposis (FAP).
The new FAP registration trial will have the potential to provide a nonsurgical treatment option to both physicians and patients with FAP.
Flynpovi has the potential to make a meaningful difference for patients with FAP by bringing this innovative treatment to market. The renew of worldwide rights to Flynpovi for FAP patients, and internal expertise, experience with health authorities, relationship with FAP experts throughout the US and Europe and commitment to FAP patients and their families, in combination with the positive results from the FAP-310 trial, will provide a solid foundation for designing and executing a successful registration trial that will have the potential to impact patients with FAP globally.
